The Technical Analyst
VanEck Vectors [PPH]
Exchange: NASDAQ
VanEck Vectors Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.32% $85.14
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 983.11 mill |
| EPS: | 4.14 |
| P/E: | 20.57 |
| Earnings Date: | N/A |
| SharesOutstanding: | 11.55 mill |
| Avg Daily Volume: | 0.125 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.40x |
| Company: PE 20.57 | sector: PE 14.70 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.19x |
| Company: PE 20.57 | industry: PE 17.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 84.33 - 85.95 ( +/- 0.95%) |
| ATR Model: 14 days |
Forecast:
16:00 - $85.14
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $85.14
Forecast 2: 16:00 - $85.14
Forecast 3: 16:00 - $85.14
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $85.14 (0.32% ) |
| Volume | 0.0729 mill |
| Avg. Vol. | 0.125 mill |
| % of Avg. Vol | 58.19 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $86.92 | N/A | Active |
|---|
PPH
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Latest News
2024-04-17 11:00:19 - Zacks Investment Research
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
2024-04-17 04:30:36 - InvestorPlace
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
People are interested in ETFs for weight loss because of Oprah's TV show “Shame, Blame, and the Weight Loss Revolution,” which was about weight loss drugs. A lot of people are upset that she's talking to patients and doctors about using prescription drugs to lose weight, but it's still causing a stir.
2024-03-08 07:21:14 - Zacks Investment Research
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.
2024-03-07 13:43:42 - InvestorPlace
The Top 3 ETFs to Buy in March 2024
Top ETFs to buy offer a smart solution for those looking to diversify their portfolios without the hassle. In the investment realm, diversification remains a key aspect of a sound investment strategy, but achieving it may feel like a Herculean task.
2024-02-26 14:12:31 - InvestorPlace
The 3 Hottest Healthcare ETFs to Buy in 2024
Healthcare stocks started the year off very strongly as investors cheered the sector's advances. Among the sector's catalysts have been continued, strong enthusiasm for a new class of weight-loss drugs called GLP-1 and Nvidia's decision, disclosed earlier this month, to invest in a medical imaging company and a firm that uses artificial intelligence ( AI ) to speed up the drug discovery process.
2024-02-19 09:50:24 - Zacks Investment Research
Pharma ETF (PPH) Hit a 52-Week High
Investors seeking momentum may have iShares VanEck Pharmaceutical ETF PPH on radar now. The fund recently hit a new 52-week high.
2024-02-12 14:01:05 - Zacks Investment Research
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
2024-01-19 07:03:28 - Seeking Alpha
PPH: Ignore The Election Scare, Buy Pharma And Healthcare
Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms of performance and liquidity. The fund is undervalued compared to the projected earnings growth of its top holdings, making it a compelling pick for investors.
2024-01-17 23:22:58 - Seeking Alpha
Healthcare In 2024: Navigating The Biopharma Bull Run
The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to adjust drug prices in line with inflation, providing advantage in inflationary environment.
2024-01-08 11:17:26 - Zacks Investment Research
5 ETF Zones Scaling New Highs at the Start of 2024
The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs.